Floatz logo

Palonosetron

Chemotherapy-Induced Toxicity

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySmall moleculePhase 4 / ApprovedActive
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Chemotherapy-Induced Toxicity cohort.

Asset / SponsorPhaseRating
Dexasone
Instituto do Cancer do Estado de São Paulo
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
HR20013
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3BB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB
Netupitant
Instituto Brasileiro de Controle do Cancer
Phase 3BB

View all 50 →

Same molecule, other indications

Palonosetron is also rated in:

cancer of unknown primary siteDormant
BB
Indicative · Phase 3
69 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
BB
Indicative · Phase 3
64 / 100
View asset →
lymphomaDormant
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →